AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$IRIX

Dizon Romeo R purchased $2K of IRIX

Dizon Romeo R (Chief Financial Officer) purchased 2,354 shares of IRIDEX CORP (IRIX) at $0.65 on 2026-09-14.

Original reporting
SEC EDGAR · Dizon Romeo R
Published Sep 14, 2026, 3:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 3:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRIX
Neutral
low confidence
Mentioned
$IRIX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRIXNeutralLow
01

Why it matters

The purchase is modest and unlikely to affect IRIDEX's stock price in the short term.

02

Market read

Limited relevance; primarily of interest to insiders‑tracking strategies.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 3/10Timing: same-day filing

Background

Form 4 filing reports insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$IRIXNeutralLow confidence
Context

CFO Romeo Dizon bought 2,354 shares of IRIDEX at $0.65 each, total $1,530.10.

Expected impact

minimal impact, no immediate price change expected

Evidence & confidence

Purchase size is tiny relative to float and market cap; CFO already holds large position.

Market effects

Sector

None; insider activity does not affect sector trends.

Regional

None; micro‑cap event limited to IRIDEX.

Global

None

Counterpoint

What could challenge this read

Even a small CFO purchase could signal confidence, but size is too small to act on.

Key entities

  • Company
    IRIDEX Corp

    Medical device manufacturer listed on NASDAQ under IRIX.

  • Individual
    Romeo Dizon

    Chief Financial Officer of IRIDEX.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRIX insider trading history →

Related articles

$IRIXMedAI 8/10

Iridex Reports Sustained Glaucoma Benefits With MicroPulse Laser Therapy At Two Years

Iridex (IRIX) reported a two-year study showing sustained IOP reductions and lower medication use in glaucoma patients treated with its MicroPulse laser therapy. The study, published in the International Journal of Ophthalmology, involved 84 eyes from 53 patients. Mean IOP decreased from 22.32 mmHg to 14.05 mmHg, and medication use fell from 2.96 to 2.38. IRIX shares traded between $0.61 and $1.65 over the past year, closing at $0.89 on Friday.

rttnews.com
$IRIXLowAI 8/10

Iridex reports 2-year glaucoma study shows sustained IOP reduction

Iridex (IRIX) reported a 2-year study showing sustained intraocular pressure reduction in glaucoma patients using its MicroPulse Technology. The study, published in the International Journal of Ophthalmology, involved 84 eyes of 53 patients. Mean intraocular pressure decreased from 22.32 mmHg to 14.05 mmHg over 24 months. The company manufactures laser-based medical systems for ophthalmology.

investing.com
$IRIXMedAI 8/10

Iridex study shows two-year glaucoma treatment outcomes

Iridex Corporation (IRIX) published a two-year study on glaucoma treatment using its MicroPulse Technology, showing significant intraocular pressure reduction and medication decrease. The study, led by Dr. Michele Lanza, was published in the International Journal of Ophthalmology and reported no complications. Iridex manufactures laser-based medical systems for glaucoma and retinal diseases.

investing.com
$IRIXMedAI 8/10

A glaucoma laser treatment lowered eye pressure and medicine use over two years.

Iridex Corporation announced a two-year study showing its MicroPulse TLT laser treatment reduced intraocular pressure and medication use in glaucoma patients. The study, published in the International Journal of Ophthalmology, involved 84 eyes of 53 patients. Mean IOP decreased from 22.32 mmHg to 14.05 mmHg, and medication use dropped from 2.96 to 2.38. The company's CEO highlighted the positive outcomes and commitment to advancing glaucoma treatments.

stocktitan.net
$IRIXMed

IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 Surges 35% as Company

IRIDEX Corp (IRIX) reported Q2 2026 earnings, highlighting a 35% surge in Cyclo-G6 probe sales. CEO Patrick Mercer expects low single-digit retina growth for the year, driven by regulatory approvals and promotions, despite headwinds in the Middle East and China. The company placed fewer Cyclo-G6 systems due to regulatory delays but anticipates higher numbers in Q4. Glaucoma growth was broad-based, with strong US and international performance. Revenue decline was attributed to retina business and

yahoo.com
$IRIXMed

Iridex Reports Second Quarter 2026 Financial Results

IRIDEX CORP (IRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Iridex Reports Second Quarter 2026 Financial Results MOUNTAIN VIEW, Calif., August 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for

SEC EDGAR 8-K